Trials / Completed
CompletedNCT00532350
Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Efficacious Dose of QAT370 Compared to Open-label Tiotropium Bromide Following Once Daily Dosing for 7 Days in COPD Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and tolerability of QAT370 compared to tiotropium in patients with COPD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QAT370 | |
| DRUG | Placebo | |
| DRUG | Tiotropium |
Timeline
- Start date
- 2007-07-01
- Completion
- 2008-01-01
- First posted
- 2007-09-20
- Last updated
- 2020-12-19
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00532350. Inclusion in this directory is not an endorsement.